Fresenius Kabi has marked the start of US biosimilar competition to Actemra (tocilizumab), launching its Tyenne (tocilizumab-aazg) version in an intravenous formulation, which it said would provide “increased access and an affordable, high-quality, and safe treatment option for US patients.”
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Tyenne Version Is Approved In SC And IV Formulations; Rival Biogen Is Yet To Launch
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.
